The main purpose of this longitudinal study was to evaluate the frequency of HPV infection in patients with residual or recurrent CIN.
Methods
797 consecutive patients with CIN, treated with conization, were included. In 38 patients with residual or recurrent CIN in whom reconization was performed, infection with high-risk HPV types was analyzed.
Results
Reconization was performed in 4.8% of patients. Before reconization, 21 patients (55.3%) were infected with high-risk HPV and 17 patients (44.7%) were HPV negative. Among the HPV-negative patients, two (11.8%) had CIN 1, five (29.4%) CIN 2, nine (52.9%) CIN 3 and one patient (5.9%) had microinvasive cancer of the uterine cervix. The difference in frequency of infection with high-risk HPV was not significant (chi-square 0.372; p>0.05).
Conclusions
On the basis of the study results it is not possible to recommend the HPV test as the only method of detection of residual or recurrent CIN after conization.
GunasekeraP.C., PhippsJ.H., LewisB.W.: Large loop excision of the transformation zone (LLETZ) compared to carbon dioxide laser in the treatment of CIN: a superior mode of treatment. Br J Obstet Gynaecol, 97: 995–998, 1990.
2.
BenedetJ.L., MillerD.M., NickersonK.G.: Results of conservative management of cervical intraepithelial neoplasia. Obstet Gynecol, 79: 105–110, 1992.
3.
HillemannsP., KimmigR., DanneckerC., NoorzaiT., DieboldJ., ThalerC.J., HeppH.: LEEP versus cold knife conization for treatment of cervical intraepithelial neoplasias. Zentralbl Gynäkol, 122: 35–42, 2000.
4.
MalufP.J., AdadS.J., MurtaE.F.: Outcome after conization for cervical intraepithelial neoplasia grade III: relation with surgical margins, extension to the crypts and mitoses. Tumori, 90: 473–477, 2004.
ElfgrenK., BistolettiP., DillnerR., WalboomersJ.M., MeijerC.J., DillnerJ.: Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol, 174: 937–942, 1996.
7.
ChuaK.L., HjerpeA.: Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol, 66: 108–113, 1997.
8.
DanneckerC., HillemannsP., HeppH.: HPV-Nachweis in der Nachsorge bei CIN. Gynäkologe, 36: 331–340, 2003.
9.
BollenL.J., Tjong-A-HungS.P., van der VeldenJ., MolB.W., BoerK., ten KateF.J., BlekerO.P., ScheggetJ.: Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia. Sex Transm Dis, 24; 456–460, 1997.
10.
DistefanoA.L., PicconiM.A., AlonioL.V., DalbertD., MuralJ., BarttO., BazanG., CervantesG., LizanoM., CarrancaA.G., TeyssieA.: Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. Infect Dis Obstet Gynecol, 6: 214–219, 1998.
11.
KanamoriY., KigawaJ., MinagawaY., IrieT., OishiT., ItamochiH., ChengX., TerakawaN.: Residual disease and presence of human papillomavirus after conization. Oncology, 55: 517–520, 1998.
12.
StrandA., WilanderE., ZehbeI., RylanderE.: High risk HPV persists after treatment of genital papillomavirus infection but not after treatment of cervical intraepithelial neoplasia. Acta Obstet Gynecol Scand, 76: 140–144, 1997.
13.
CruickshankM.E., SharpL., ChambersG., SmartL., MurrayG.: Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia. Br J Obstet Gynecol, 109: 579–581, 2002.
14.
AcladiousN.N., SuttonC., MandalD., HopkinsR., ZaklamaM., KitchenerH.: Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia. Int J Cancer, 98: 435–439, 2002.
15.
KjellbergL., WadellG., BergmanF., IsakssonM., AngstromT., DillnerJ.: Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol, 183: 1238–1242, 2000.
16.
TjiongM.Y., OutT.A., Ter ScheggetJ., BurgerM.P.M., Van der VangeN.: Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: A review. Int J Gynecol Cancer, 11: 9–17, 2001.
17.
GuijonF., ParaskevasM., McNicolP.: Human papillomavirus infection and the size and grade of cervical intraepithelial neoplastic lesions associated with failure of therapy. Int J Gynaecol Obstet, 42: 137–142, 1993.
18.
KaufmanR.H., AdamE.: Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?Gynecol Oncol,70: 317–318, 1998.
19.
MurtaE.F.C., ResendeA.V., SouzaM.A.H., AdadS.J., SalumR.: Importance of surgical margins in conization for cervical intraepithelial neoplasia grade III. Arch Gynecol Obstet, 263: 42–44, 1999.
20.
BretelleF., CravelloL., YangL., BenmouraD., RogerV., BlancB.: Conisations non in sano: quelle attitude adopter?Ann Chir,125: 444–449, 2000.
21.
MitsuhashiA., TanakaH., TanakaN., SugitaM., ShirasawaH., TokitaH., EdaH., SekiyaS.: Establishment and characterization of a new HPV-negative squamous cell carcinoma cell line (Yumoto) from the human uterine cervix. Gynecol Oncol, 70: 339–347, 1998.
22.
RemminkA.J., WalboomersJ.M., HelmerhorstT.J., VoorhorstF.J., RozendaalL., RisseE.K., MeijerC.J., KenemansP.: The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer, 61: 306–311, 1995.
23.
NobbenhuisM.A., WalboomersJ.M., HelmerhorstT.J., RozendaalL., RemminkA.J., RisseE.K., van der LindenH.C., VoorhorstF.J., KenemansP., MeijerC.J.: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet, 354: 20–25, 1999.
24.
HoG.Y., BiermanR., BeardsleyL., ChangC.J., BurkR.D.: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 338: 423–428, 1998.
25.
FenJ., YoshinouchiM., NakamuraK., KodamaJ., NasuY., YamatoK., HiramatsuY.: Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status. Oncol Rep, 12: 375–379, 2004.
26.
ParaskevaidisE., ArbynM., SotiriadisA., DiakomanolisE., Martin-HirschP., KoliopoulosG., MakrydimasG., TofoskiJ., RoukosD.H.: The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev, 30: 205–211, 2004.
27.
ElfgrenK., JacobsM., WalboomersJ.M., MeijerC.J., DillnerJ.: Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol, 100: 965–971, 2002.
28.
SarianL.O., DerchainS.F.M., AndradeL.A.A., TambasciaJ., MoraisS.S., SyrjänenK.J.: HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecol Oncol, 94: 181–186, 2004.
